U 89674
U 89674 is a nonnucleoside HIV-1 reverse transcriptase inhibitor with no cytotoxic effect on cells at concentrations of 10 μM or lower over 7 days. U 89674 modulates reverse transcriptase activity, interfering with HIV-1 replication. U 89674 inhibits replication of HIV-1 laboratory strains and primary HIV-1 isolates in immune cells. U 89674 delays virus-induced cell killing in mixed cultures of uninfected and HIV-1-infected cells. U 89674 can be used for the research of HIV-1 infection.
For research use only. We do not sell to patients.
- CAS No.: 144674-89-5
- Formula: C24H31N7O
- Molecular Weight:433.56
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| MT2 | IC50 |
0.22 μM
|
Inhibition of HIV-1ₗₐᵥ replication (measured as reduction in viral p24 antigen synthesis) in MT-2 cells incubated for 7 days by MTT assay.
Inhibition of HIV-1ₗₐᵥ replication (measured as reduction in viral p24 antigen synthesis) in MT-2 cells incubated for 7 days by MTT assay.
|
004268229291213E |
In Vitro
U 89674 (0.22-10 μM; 7 days) potently inhibits HIV-1lav replication in MT-2 cells with an IC50 of 0.22 μM, causing 93% inhibition at 1 μM, and shows no cytotoxicity at concentrations up to 10 μM[1].
U 89674 (1 μM; 7 days) potently inhibits replication of all tested primary HIV-1 isolates in PBMC, achieving 99-100% inhibition of p24 antigen synthesis[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
Chemical Information
-
CAS No. 144674-89-5
-
Molecular Weight 433.56
-
Formula C24H31N7O
-
SMILES
O=C(C1=CC=2C=C(N=CN(C)C)C=CC2N1)N3CCN(C4=NC=CC=C4NC(C)C)CC3
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Research Protocol for Infectious Diseases
Infectious-disease experiments test how pathogens interact with host barriers, innate immune receptors, inflammatory signaling, pathogen replication, and tissue injury; pattern-recognition receptors such as TLRs, RIG-I-like receptors, NOD-like receptors, and inflammasomes detect microbial molecules and activate NF-κB, interferon, and cytokine responses. The central hypothesis is that infection severity reflects the balance between pathogen burden and host response: protective inflammation restricts pathogen growth, whereas excessive or mislocalized inflammation contributes to tissue damage and disease phenotype. Unresolved questions include which host pathways are protective versus pathogenic, why some infection models fail to translate to human disease, and which combined readouts best predict clinically relevant infection outcomes.
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)